Age-related Macular Degeneration Market (2022 - 2032)
Age-related Macular Degeneration Market Forecast By Product (Eylea, Lucentis, Beovu and Others), By Disease Type (Dry AMD and Wet AMD), By Distribution Channel (Hospital Pharmacy, Specialty Pharmacy and Online Pharmacy) & By Region (North America, Europe, Asia Pacific) - Global Market Insights 2022 to 2032
Core Findings
FREE CustomizationAge-related Macular Degeneration Market Outlook (2022 to 2032)
The global age-related macular degeneration market reached a valuation of US$ 11 Billion by 2022. Furthermore, across the 2022 to 2032 period of assessment, growth is expected to accelerate at a whopping 6.2% CAGR, reaching US$ 20 Billion.
Age-related macular degeneration (AMD), often known as macular degeneration is a disorder that causes loss of central vision owing to thinning of the retina's macula. Age-related macular degeneration is more common in the elderly population and can result in irreversible visual loss in persons over the age of 60.
Dry age-related macular degeneration (Dry AMD) and wet age-related macular degeneration (Wet AMD) are the two kinds of age-related macular degeneration (wet AMD). The most prevalent kind of macular degeneration is dry age-related macular degeneration, in which the macula thins with age, resulting in loss of central vision.
Dry age-related macular degeneration does not have a therapy. Wet age-related macular degeneration is a less frequent kind in which aberrant blood vessels develop underneath the retina. Anti-vascular endothelial growth factor (anti-VEGF) injections can be used to treat wet age-related macular degeneration.
AMD is a leading cause of visual loss among the elderly in the United States. The growing senior population in the United States and other nations is predicted to considerably increase the prevalence of AMD in the coming years.
| Report Attributes | Details |
|---|---|
| Expected Market Value (2022) | US$ 11 Billion |
| Projected Forecast Value (2032) | US$ 20 Billion |
| Global Growth Rate (2022 to 2032) | 6.2% CAGR |
| Prominent Service Players | F. Hoffmann-La Roche Ltd.; Novartis AG; Bayer AG; Pfizer Inc.; Bausch Health Companies Inc.; Regeneron Pharmaceuticals Inc.; Amgen Inc.; Biogen; Samsung Bioepis |
2017 to 2022 Revenue Analysis of Age-related Macular Degeneration Market vs. Growth Outlook 2022 to 2032
The global market for Age-related Macular Degeneration expanded at under 5.7% CAGR from 2017 to 2021.
The global market for AMD is being driven by an increase in the number of AMD patients. According to the American Academy of Ophthalmology, about 11 million people in the United States suffer from AMD, and the prevalence of AMD is particularly high in Southeast Asian and Sub-Saharan African nations due to vitamin A insufficiency.
Another key driver for the age-related macular degeneration market is the expansion of reimbursement benefits for AMD medications. Medicare established a National Reimbursement Rate in the United States based on the regular cost of the medicine.
In this case, the agency covers about 80% of the cost of bevacizumab and ranibizumab injections, with the remaining 20% co-paid. Medicare Part B is a medical insurance that covers eye disorders and diagnostic testing, as well as particular treatment conditions such as AMD. The AMD market has several key obstacles, including a shortage of skilled ophthalmologists, high medication costs for wet AMD, and the related high risk.
Based on the aforementioned trends, the global market Age-related Macular Degeneration is poised to surge at a 6.2% CAGR, reaching US$ 20 Billion by 2032.
Key Market Drivers Influencing Age-related Macular Degeneration Industry Expansion
Increasing Government Healthcare Spending to Foster Market Growth Prospects
Increasing government healthcare spending to lessen patient healthcare burden is one of the main growth factors for the age-related macular degeneration market. Globally, the healthcare burden has grown significantly and has become a serious problem for both patients and healthcare professionals. Some of the causes contributing to increased healthcare expenditures are the high cost of modern treatment technologies and rising physician fees.
As a result, governments in several nations have raised total healthcare spending in order to improve access to cheap treatment alternatives. Hence, global market growth is being supported.
Furthermore, an enormous pipeline of AMD medications is a major driver of the age-related macular degeneration industry. Although there are currently few therapeutic options for AMD, prominent industry participants are focusing on developing medications for this indication in order to satisfy the rising unmet medical requirements of people suffering from the condition.
Key Challenges encountered by Age-related Macular Degeneration Industry
Growing Off-Label Usage of Medications for the Treatment of AMD to Hamper the Market Growth
The growing off-label usage of medications for the treatment of AMD is stifling the expansion of the age-related macular degeneration industry. Off-label drug usage is using a medicine that has not been approved by the US Food and Drug Administration for a different ailment or medical condition, in a different method or dose (USFDA).
For example, ophthalmologists frequently utilize intraocular injections of Avastin (off-label) to treat AMD rather than the more costly Lucentis, because the two medications have similar effects.
Country-wise Analysis
How will the U.S Perform in the Global Age-related Macular Degeneration Industry Landscape?
Product Approvals and Releases of Novel Age-Related Macular Degeneration Therapy Treatments to Boost the Market Growth
Because of product approvals and releases of novel age-related macular degeneration therapy treatments in the area, North America accounted for the greatest market share in 2021.
For example, Novartis got Food and Drug Administration (FDA) clearance in October 2019 for Beovu (brolucizumab) injection for the treatment of wet age-related macular degeneration (AMD).
Furthermore, in August 2018, Regeneron Pharmaceuticals, Inc. gained FDA clearance for a supplement Biologics License Application (sBLA) for EYLEA injection for the treatment of wet age-related macular degeneration (wet AMD).
Furthermore, several mergers, collaborations, and acquisitions by industry participants are likely to boost market expansion throughout the projection period.
For example, Boehringer Ingelheim entered into a co-development and license agreement with Inflammasome Therapeutics Inc. in September 2019 to develop three therapies for patients suffering from retinal diseases such as age-related macular degeneration (AMD), diabetic retinopathy (DR), and diabetic macular edoema (DME). The collaboration is intended to boost Boehringer Ingelheim's eye disease pipeline portfolio.
How will the Growth of Age-related Macular Degeneration Market Escalate across China?
Rising Prevalence of Eye Illness to Enhance the Market Prospects
Growing healthcare spending, rising prevalence of eye illness, and the development of multinational organisations are likely to drive growth in the Asia-Pacific age-related macular degeneration market. The region's large elderly population and illness burden are important drivers to its fast growth. Government measures that make pricey anti-VEGF medications more available to the general population may help drive market growth.
Country-wise Forecast CAGRs for the Age-related Macular Degeneration Market
| Country | CAGR |
|---|---|
| U.K | 5.7% |
| India | 5.5% |
| South Korea | 5% |
| China | 5.9% |
| U.S | 6% |
Category-wise Insights
Which is the Most Sought-after Product Category?
The Eylea Segment to Boost the Market’s Growth
Over the assessment period, the eylea category dominated the market. This supremacy is due to extensive market penetration and patent protection. Furthermore, Beovu patients reported four times greater intraocular inflammation than Eylea patients, according to study investigations. Such variables favor Eylea over the experimental medication Beovu.
Lucentis is predicted to have the biggest market share in the next years, followed by Eylea, due to factors such as the introduction of a new drug delivery method. Susvimo, a refillable implant for Lucentis, was approved by the US Food and Drug Administration in October 2021. Susvimo requires ranibizumab refills every six months. This reduces the frequency of administration, answering a patient's unmet demand.
Which Segment to Remain Dominant in the Distribution Channel Category?
The Hospital Pharmacy Segment to Enhance Growth Prospects
During the forecast period, the hospital pharmacy sector dominated the global market. The growth in the prevalence of age-related macular degeneration (AMD) and hospitalization for treatment can be linked to this dominance.
The Royal National Institute of Blind People (RNIB) estimated that around 25.3 million people were at high risk of developing age-related macular degeneration (AMD) in 2020. The majority of patients are treated with drugs such as Lucentis, Eylea, and Beovu, which are administered intravenously in hospitals under the supervision of competent specialists.
As a result, rising demand for AMD treatment is expected to boost hospital visits, propelling the market.
Age-related Macular Degeneration Market- Competitive Landscape
Prominent players in the Age-related Macular Degeneration Industry are taking advantage of the rapidly increasing demand for the Age-related Macular Degeneration in various applications. To further their outreach, players are relying on collaborations, partnerships and acquisitions with existing small, medium and large-scale vendors. Some prominent market developments are as follows :
- In November 2022, Bayer announced today the acquisition of Targenomix, a German biotech start-up. The Max Planck Institute for Molecular Plant Physiology (MPI MPP) spin-off identifies new mechanisms of action for crop protection chemicals using modern systems biology and computational life science technologies. Targenomix's expertise, personnel, and platforms will be critical in delivering on Bayer's commitment to the design of safe and effective molecules, as well as in accelerating the discovery and development of molecules with the potential to make agricultural production more sustainable in the face of dynamic challenges such as climate change and increasing weed, disease, and insect resistance.
Key Segments Covered in the Age-related Macular Degeneration Industry Survey
-
By Product :
- Eylea
- Lucentis
- Beovu
- Others
-
By Disease Type :
- Dry AMD
- Wet AMD
-
By Distribution Channel :
- Hospital Pharmacy
- Specialty Pharmacy
- Online Pharmacy
-
By Region :
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Table of Content
- 1. Executive Summary
- 2. Market Overview
- 3. Market Background
- 4. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032
- 5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Product
- 5.1. Eylea
- 5.2. Lucentis
- 5.3. Beovu
- 5.4. Others
- 6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Disease Type
- 6.1. Dry AMD
- 6.2. Wet AMD
- 7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Distribution Channel
- 7.1. Hospital Pharmacy
- 7.2. Specialty Pharmacy
- 7.3. Online Pharmacy
- 8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region
- 8.1. North America
- 8.2. Latin America
- 8.3. Europe
- 8.4. Asia Pacific
- 8.5. MEA
- 9. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
- 10. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
- 11. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
- 12. Asia Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
- 13. MEA Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
- 14. Key Countries Market Analysis
- 15. Market Structure Analysis
- 16. Competition Analysis
- 16.1. Nestlé
- 16.2. SCHELL & KAMPETER, INC.
- 16.3. The J.M. Smucker Company
- 16.4. Hill's Pet Nutrition, Inc.
- 16.5. Addiction Foods
- 16.6. Wellness Pet Company
- 16.7. Spectrum Brands, Inc.
- 16.8. Unicharm Corporation
- 16.9. Blue Buffalo Co., Ltd.
- 16.10. Mars, Incorporated
- 17. Assumptions & Acronyms Used
- 18. Research Methodology
List Of Table
Table 01: Global Market Value (US$ Mn) Forecast by Region, 2017 to 2032
Table 02: Global Market Volume (Tonnes) Forecast by Region, 2017 to 2032
Table 03: Global Market Value (US$ Mn) Forecast by Product, 2017 to 2032
Table 04: Global Market Volume (Tonnes) Forecast by Product, 2017 to 2032
Table 05: Global Market Value (US$ Mn) Forecast By Disease Type, 2017 to 2032
Table 06: Global Market Volume (Tonnes) Forecast By Disease Type, 2017 to 2032
Table 07: Global Market Value (US$ Mn) Forecast by Distribution Channel, 2017 to 2032
Table 08: Global Market Volume (Tonnes) Forecast by Distribution Channel, 2017 to 2032
Table 09: North America Market Value (US$ Mn) Forecast by Country, 2017 to 2032
Table 10: North America Market Volume (Tonnes) Forecast by Country, 2017 to 2032
Table 11: North America Market Value (US$ Mn) Forecast by Product, 2017 to 2032
Table 12: North America Market Volume (Tonnes) Forecast by Product, 2017 to 2032
Table 13: North America Market Value (US$ Mn) Forecast By Disease Type, 2017 to 2032
Table 14: North America Market Volume (Tonnes) Forecast By Disease Type, 2017 to 2032
Table 15: North America Market Value (US$ Mn) Forecast by Distribution Channel, 2017 to 2032
Table 16: North America Market Volume (Tonnes) Forecast by Distribution Channel, 2017 to 2032
Table 17: Latin America Market Value (US$ Mn) Forecast by Country, 2017 to 2032
Table 18: Latin America Market Volume (Tonnes) Forecast by Country, 2017 to 2032
Table 19: Latin America Market Value (US$ Mn) Forecast by Product, 2017 to 2032
Table 20: Latin America Market Volume (Tonnes) Forecast by Product, 2017 to 2032
Table 21: Latin America Market Value (US$ Mn) Forecast By Disease Type, 2017 to 2032
Table 22: Latin America Market Volume (Tonnes) Forecast By Disease Type, 2017 to 2032
Table 23: Latin America Market Value (US$ Mn) Forecast by Distribution Channel, 2017 to 2032
Table 24: Latin America Market Volume (Tonnes) Forecast by Distribution Channel, 2017 to 2032
Table 25: Europe Market Value (US$ Mn) Forecast by Country, 2017 to 2032
Table 26: Europe Market Volume (Tonnes) Forecast by Country, 2017 to 2032
Table 27: Europe Market Value (US$ Mn) Forecast by Product, 2017 to 2032
Table 28: Europe Market Volume (Tonnes) Forecast by Product, 2017 to 2032
Table 29: Europe Market Value (US$ Mn) Forecast By Disease Type, 2017 to 2032
Table 30: Europe Market Volume (Tonnes) Forecast By Disease Type, 2017 to 2032
Table 31: Europe Market Value (US$ Mn) Forecast by Distribution Channel, 2017 to 2032
Table 32: Europe Market Volume (Tonnes) Forecast by Distribution Channel, 2017 to 2032
Table 33: Asia Pacific Market Value (US$ Mn) Forecast by Country, 2017 to 2032
Table 34: Asia Pacific Market Volume (Tonnes) Forecast by Country, 2017 to 2032
Table 35: Asia Pacific Market Value (US$ Mn) Forecast by Product, 2017 to 2032
Table 36: Asia Pacific Market Volume (Tonnes) Forecast by Product, 2017 to 2032
Table 37: Asia Pacific Market Value (US$ Mn) Forecast By Disease Type, 2017 to 2032
Table 38: Asia Pacific Market Volume (Tonnes) Forecast By Disease Type, 2017 to 2032
Table 39: Asia Pacific Market Value (US$ Mn) Forecast by Distribution Channel, 2017 to 2032
Table 40: Asia Pacific Market Volume (Tonnes) Forecast by Distribution Channel, 2017 to 2032
Table 41: MEA Market Value (US$ Mn) Forecast by Country, 2017 to 2032
Table 42: MEA Market Volume (Tonnes) Forecast by Country, 2017 to 2032
Table 43: MEA Market Value (US$ Mn) Forecast by Product, 2017 to 2032
Table 44: MEA Market Volume (Tonnes) Forecast by Product, 2017 to 2032
Table 45: MEA Market Value (US$ Mn) Forecast By Disease Type, 2017 to 2032
Table 46: MEA Market Volume (Tonnes) Forecast By Disease Type, 2017 to 2032
Table 47: MEA Market Value (US$ Mn) Forecast by Distribution Channel, 2017 to 2032
Table 48: MEA Market Volume (Tonnes) Forecast by Distribution Channel, 2017 to 2032
List Of Figures
Figure 01: Global Market Value (US$ Mn) by Product, 2022 to 2032
Figure 02: Global Market Value (US$ Mn) By Disease Type, 2022 to 2032
Figure 03: Global Market Value (US$ Mn) by Distribution Channel, 2022 to 2032
Figure 04: Global Market Value (US$ Mn) by Region, 2022 to 2032
Figure 05: Global Market Value (US$ Mn) Analysis by Region, 2017 to 2032
Figure 06: Global Market Volume (Tonnes) Analysis by Region, 2017 to 2032
Figure 07: Global Market Value Share (%) and BPS Analysis by Region, 2022 to 2032
Figure 08: Global Market Y-o-Y Growth (%) Projections by Region, 2022 to 2032
Figure 09: Global Market Value (US$ Mn) Analysis by Product, 2017 to 2032
Figure 10: Global Market Volume (Tonnes) Analysis by Product, 2017 to 2032
Figure 11: Global Market Value Share (%) and BPS Analysis by Product, 2022 to 2032
Figure 12: Global Market Y-o-Y Growth (%) Projections by Product, 2022 to 2032
Figure 13: Global Market Value (US$ Mn) Analysis By Disease Type, 2017 to 2032
Figure 14: Global Market Volume (Tonnes) Analysis By Disease Type, 2017 to 2032
Figure 15: Global Market Value Share (%) and BPS Analysis By Disease Type, 2022 to 2032
Figure 16: Global Market Y-o-Y Growth (%) Projections By Disease Type, 2022 to 2032
Figure 17: Global Market Value (US$ Mn) Analysis by Distribution Channel, 2017 to 2032
Figure 18: Global Market Volume (Tonnes) Analysis by Distribution Channel, 2017 to 2032
Figure 19: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032
Figure 20: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032
Figure 21: Global Market Attractiveness by Product, 2022 to 2032
Figure 22: Global Market Attractiveness By Disease Type, 2022 to 2032
Figure 23: Global Market Attractiveness by Distribution Channel, 2022 to 2032
Figure 24: Global Market Attractiveness by Region, 2022 to 2032
Figure 25: North America Market Value (US$ Mn) by Product, 2022 to 2032
Figure 26: North America Market Value (US$ Mn) By Disease Type, 2022 to 2032
Figure 27: North America Market Value (US$ Mn) by Distribution Channel, 2022 to 2032
Figure 28: North America Market Value (US$ Mn) by Country, 2022 to 2032
Figure 29: North America Market Value (US$ Mn) Analysis by Country, 2017 to 2032
Figure 30: North America Market Volume (Tonnes) Analysis by Country, 2017 to 2032
Figure 31: North America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 32: North America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 33: North America Market Value (US$ Mn) Analysis by Product, 2017 to 2032
Figure 34: North America Market Volume (Tonnes) Analysis by Product, 2017 to 2032
Figure 35: North America Market Value Share (%) and BPS Analysis by Product, 2022 to 2032
Figure 36: North America Market Y-o-Y Growth (%) Projections by Product, 2022 to 2032
Figure 37: North America Market Value (US$ Mn) Analysis By Disease Type, 2017 to 2032
Figure 38: North America Market Volume (Tonnes) Analysis By Disease Type, 2017 to 2032
Figure 39: North America Market Value Share (%) and BPS Analysis By Disease Type, 2022 to 2032
Figure 40: North America Market Y-o-Y Growth (%) Projections By Disease Type, 2022 to 2032
Figure 41: North America Market Value (US$ Mn) Analysis by Distribution Channel, 2017 to 2032
Figure 42: North America Market Volume (Tonnes) Analysis by Distribution Channel, 2017 to 2032
Figure 43: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032
Figure 44: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032
Figure 45: North America Market Attractiveness by Product, 2022 to 2032
Figure 46: North America Market Attractiveness By Disease Type, 2022 to 2032
Figure 47: North America Market Attractiveness by Distribution Channel, 2022 to 2032
Figure 48: North America Market Attractiveness by Country, 2022 to 2032
Figure 49: Latin America Market Value (US$ Mn) by Product, 2022 to 2032
Figure 50: Latin America Market Value (US$ Mn) By Disease Type, 2022 to 2032
Figure 51: Latin America Market Value (US$ Mn) by Distribution Channel, 2022 to 2032
Figure 52: Latin America Market Value (US$ Mn) by Country, 2022 to 2032
Figure 53: Latin America Market Value (US$ Mn) Analysis by Country, 2017 to 2032
Figure 54: Latin America Market Volume (Tonnes) Analysis by Country, 2017 to 2032
Figure 55: Latin America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 57: Latin America Market Value (US$ Mn) Analysis by Product, 2017 to 2032
Figure 58: Latin America Market Volume (Tonnes) Analysis by Product, 2017 to 2032
Figure 59: Latin America Market Value Share (%) and BPS Analysis by Product, 2022 to 2032
Figure 60: Latin America Market Y-o-Y Growth (%) Projections by Product, 2022 to 2032
Figure 61: Latin America Market Value (US$ Mn) Analysis By Disease Type, 2017 to 2032
Figure 62: Latin America Market Volume (Tonnes) Analysis By Disease Type, 2017 to 2032
Figure 63: Latin America Market Value Share (%) and BPS Analysis By Disease Type, 2022 to 2032
Figure 64: Latin America Market Y-o-Y Growth (%) Projections By Disease Type, 2022 to 2032
Figure 65: Latin America Market Value (US$ Mn) Analysis by Distribution Channel, 2017 to 2032
Figure 66: Latin America Market Volume (Tonnes) Analysis by Distribution Channel, 2017 to 2032
Figure 67: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032
Figure 68: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032
Figure 69: Latin America Market Attractiveness by Product, 2022 to 2032
Figure 70: Latin America Market Attractiveness By Disease Type, 2022 to 2032
Figure 71: Latin America Market Attractiveness by Distribution Channel, 2022 to 2032
Figure 72: Latin America Market Attractiveness by Country, 2022 to 2032
Figure 73: Europe Market Value (US$ Mn) by Product, 2022 to 2032
Figure 74: Europe Market Value (US$ Mn) By Disease Type, 2022 to 2032
Figure 75: Europe Market Value (US$ Mn) by Distribution Channel, 2022 to 2032
Figure 76: Europe Market Value (US$ Mn) by Country, 2022 to 2032
Figure 77: Europe Market Value (US$ Mn) Analysis by Country, 2017 to 2032
Figure 78: Europe Market Volume (Tonnes) Analysis by Country, 2017 to 2032
Figure 79: Europe Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 80: Europe Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 81: Europe Market Value (US$ Mn) Analysis by Product, 2017 to 2032
Figure 82: Europe Market Volume (Tonnes) Analysis by Product, 2017 to 2032
Figure 83: Europe Market Value Share (%) and BPS Analysis by Product, 2022 to 2032
Figure 84: Europe Market Y-o-Y Growth (%) Projections by Product, 2022 to 2032
Figure 85: Europe Market Value (US$ Mn) Analysis By Disease Type, 2017 to 2032
Figure 86: Europe Market Volume (Tonnes) Analysis By Disease Type, 2017 to 2032
Figure 87: Europe Market Value Share (%) and BPS Analysis By Disease Type, 2022 to 2032
Figure 88: Europe Market Y-o-Y Growth (%) Projections By Disease Type, 2022 to 2032
Figure 89: Europe Market Value (US$ Mn) Analysis by Distribution Channel, 2017 to 2032
Figure 90: Europe Market Volume (Tonnes) Analysis by Distribution Channel, 2017 to 2032
Figure 91: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032
Figure 92: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032
Figure 93: Europe Market Attractiveness by Product, 2022 to 2032
Figure 94: Europe Market Attractiveness By Disease Type, 2022 to 2032
Figure 95: Europe Market Attractiveness by Distribution Channel, 2022 to 2032
Figure 96: Europe Market Attractiveness by Country, 2022 to 2032
Figure 97: Asia Pacific Market Value (US$ Mn) by Product, 2022 to 2032
Figure 98: Asia Pacific Market Value (US$ Mn) By Disease Type, 2022 to 2032
Figure 99: Asia Pacific Market Value (US$ Mn) by Distribution Channel, 2022 to 2032
Figure 100: Asia Pacific Market Value (US$ Mn) by Country, 2022 to 2032
Figure 101: Asia Pacific Market Value (US$ Mn) Analysis by Country, 2017 to 2032
Figure 102: Asia Pacific Market Volume (Tonnes) Analysis by Country, 2017 to 2032
Figure 103: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 104: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 105: Asia Pacific Market Value (US$ Mn) Analysis by Product, 2017 to 2032
Figure 106: Asia Pacific Market Volume (Tonnes) Analysis by Product, 2017 to 2032
Figure 107: Asia Pacific Market Value Share (%) and BPS Analysis by Product, 2022 to 2032
Figure 108: Asia Pacific Market Y-o-Y Growth (%) Projections by Product, 2022 to 2032
Figure 109: Asia Pacific Market Value (US$ Mn) Analysis By Disease Type, 2017 to 2032
Figure 110: Asia Pacific Market Volume (Tonnes) Analysis By Disease Type, 2017 to 2032
Figure 111: Asia Pacific Market Value Share (%) and BPS Analysis By Disease Type, 2022 to 2032
Figure 112: Asia Pacific Market Y-o-Y Growth (%) Projections By Disease Type, 2022 to 2032
Figure 113: Asia Pacific Market Value (US$ Mn) Analysis by Distribution Channel, 2017 to 2032
Figure 114: Asia Pacific Market Volume (Tonnes) Analysis by Distribution Channel, 2017 to 2032
Figure 115: Asia Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032
Figure 116: Asia Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032
Figure 117: Asia Pacific Market Attractiveness by Product, 2022 to 2032
Figure 118: Asia Pacific Market Attractiveness By Disease Type, 2022 to 2032
Figure 119: Asia Pacific Market Attractiveness by Distribution Channel, 2022 to 2032
Figure 120: Asia Pacific Market Attractiveness by Country, 2022 to 2032
Figure 121: MEA Market Value (US$ Mn) by Product, 2022 to 2032
Figure 122: MEA Market Value (US$ Mn) By Disease Type, 2022 to 2032
Figure 123: MEA Market Value (US$ Mn) by Distribution Channel, 2022 to 2032
Figure 124: MEA Market Value (US$ Mn) by Country, 2022 to 2032
Figure 125: MEA Market Value (US$ Mn) Analysis by Country, 2017 to 2032
Figure 126: MEA Market Volume (Tonnes) Analysis by Country, 2017 to 2032
Figure 127: MEA Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 128: MEA Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 129: MEA Market Value (US$ Mn) Analysis by Product, 2017 to 2032
Figure 130: MEA Market Volume (Tonnes) Analysis by Product, 2017 to 2032
Figure 131: MEA Market Value Share (%) and BPS Analysis by Product, 2022 to 2032
Figure 132: MEA Market Y-o-Y Growth (%) Projections by Product, 2022 to 2032
Figure 133: MEA Market Value (US$ Mn) Analysis By Disease Type, 2017 to 2032
Figure 134: MEA Market Volume (Tonnes) Analysis By Disease Type, 2017 to 2032
Figure 135: MEA Market Value Share (%) and BPS Analysis By Disease Type, 2022 to 2032
Figure 136: MEA Market Y-o-Y Growth (%) Projections By Disease Type, 2022 to 2032
Figure 137: MEA Market Value (US$ Mn) Analysis by Distribution Channel, 2017 to 2032
Figure 138: MEA Market Volume (Tonnes) Analysis by Distribution Channel, 2017 to 2032
Figure 139: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032
Figure 140: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032
Figure 141: MEA Market Attractiveness by Product, 2022 to 2032
Figure 142: MEA Market Attractiveness By Disease Type, 2022 to 2032
Figure 143: MEA Market Attractiveness by Distribution Channel, 2022 to 2032
Figure 144: MEA Market Attractiveness by Country, 2022 to 2032
- FAQs -
What was the market worth for Age-related Macular Degeneration in 2022?
As of 2022, the Age-related Macular Degeneration market was valued at US$ 11 Billion.
From 2017 to 2021, what was the documented growth rate for the Age-related Macular Degeneration market?
According to Fact.MR, a CAGR of 5.7% was recorded for the Age-related Macular Degeneration market from 2017 to 2021.
At what percentage will the industry expand during the 2022 to 2032 period of assessment?
From 2022 to 2032, the Age-related Macular Degeneration industry is poised to flourish at a 6.2% CAGR.
What is the expected closing market value for Age-related Macular Degeneration in 2032?
By 2032, the Age-related Macular Degeneration landscape is slated to reach a valuation of US$ 20 Billion.
By product, which segment is likely to experience the fastest growth rate?
The eylea category is expected to grow the fastest during the forecast period.
Which is the most preferred distribution channel category of Age-related Macular Degeneration?
By distribution channel, the hospital pharmacy segment is expected to dominate the market.
How will the U.K market for Age-related Macular Degeneration flourish until 2032?
As per Fact.MR’s projections, the market for Age-related Macular Degeneration in the UK will likely expand at a 5.7% CAGR.
What will be the growth scenario for the market in China until 2032?
China is poised to yield a CAGR of 5.9% with respect to Age-related Macular Degeneration in 2032.
Related Reports
Age-related Macular Degeneration Market